Keywords: UK, NICE, SMC, Novartis, Afinitor, Tasigna, Bristol-Meyes Squibb, Sprycel, EliLilly, Alimta, Janssen Cilag, Stelara
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
Article | 9 February 2010
In draft guidance, published today, the UK’s National Institute for Health and Clinical Excellence (NICE) says it has been unable to recommend Swiss drug major Novartis’ Afinitor (everolimus) for the second line treatment of advanced renal cell carcinoma.
This draft guidance is now available for public consultation. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
